Robert J. Hombach has bought stock on 4 days since Jan 2020

Robert J. “Bob” Hombach is a corporate individual insider and experienced healthcare finance executive who serves on the Board of Directors of Seaport Therapeutics, Inc. and chairs its Audit Committee.( A former executive vice president, chief financial officer, and chief operations officer of Baxalta, he played a key role in Baxalta’s spin-off from Baxter International, where he previously served as corporate vice president and chief financial officer and led strategic restructuring and venture investment activities.(

Hombach brings more than three decades of financial and operational leadership in the biopharmaceutical and medical device sectors, and he currently holds or has held board and audit committee roles at several public companies, including BioMarin Pharmaceutical, embecta, Henry Schein, CarMax, and Aptinyx.( Recognized by IR Magazine as a Top 100 U.S. CFO in 2013 and 2014, he is also a National Association of Corporate Directors Board Leadership Fellow.( He holds an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management and a B.S. in Finance, cum laude, from the University of Colorado.(

Written by Perplexity from public sources.